Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad

Research output: Contribution to journalReview article

4 Scopus citations


Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

Original languageEnglish (US)
Pages (from-to)569-580
Number of pages12
JournalDrug design, development and therapy
StatePublished - Jan 1 2019



  • ALK inhibitors
  • ALK positive
  • brigatinib
  • non-small cell lung cancer
  • TKI

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this